Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels

[1]  R. Petersen,et al.  Phosphorylated tau fluid biomarker sites recognize earlier neurofibrillary tangle maturity levels in the postmortem Alzheimer’s disease brain , 2021, bioRxiv.

[2]  O. Hansson.  Biomarkers for neurodegenerative diseases , 2021, Nature Medicine.

[3]  R. Bateman,et al.  Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau , 2021, EMBO molecular medicine.

[4]  M. Mesulam,et al.  Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. , 2020, Journal of neuropathology and experimental neurology.

[5]  K. Blennow,et al.  Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected , 2020, EMBO molecular medicine.

[6]  Christoph N Schlaffner,et al.  Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease , 2020, Cell.

[7]  W. Scheper,et al.  Untangling the origin and function of granulovacuolar degeneration bodies in neurodegenerative proteinopathies , 2020, Acta neuropathologica communications.

[8]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[9]  R. Bateman,et al.  Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease , 2020, The Journal of experimental medicine.

[10]  John L. Robinson,et al.  Distribution patterns of tau pathology in progressive supranuclear palsy , 2020, Acta Neuropathologica.

[11]  I. Katona,et al.  Aggregates of RNA Binding Proteins and ER Chaperones Linked to Exosomes in Granulovacuolar Degeneration of the Alzheimer's Disease Brain. , 2020, Journal of Alzheimer's disease : JAD.

[12]  Philip S. Insel,et al.  Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease , 2020, Science Advances.

[13]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[14]  Nick C Fox,et al.  A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease , 2020, Nature Medicine.

[15]  D. Airey,et al.  Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease , 2020 .

[16]  K. Blennow,et al.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.

[17]  B. de Strooper,et al.  Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease , 2019, Acta Neuropathologica.

[18]  W. Scheper,et al.  Granulovacuolar degeneration bodies are neuron-selective lysosomal structures induced by intracellular tau pathology , 2019, Acta Neuropathologica.

[19]  S. Lim,et al.  MSC exosome works through a protein-based mechanism of action , 2018, Biochemical Society transactions.

[20]  Publisher's Note , 2018, Anaesthesia.

[21]  Dietmar R. Thal,et al.  Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity , 2016, Acta Neuropathologica.

[22]  H. Shill,et al.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program , 2015, Neuropathology : official journal of the Japanese Society of Neuropathology.

[23]  T. Yamawaki,et al.  Granulovacuolar Degenerations Appear in Relation to Hippocampal Phosphorylated Tau Accumulation in Various Neurodegenerative Disorders , 2011, PloS one.

[24]  H. Braak,et al.  Stages of granulovacuolar degeneration: their relation to Alzheimer’s disease and chronic stress response , 2011, Acta Neuropathologica.

[25]  J. Kuret,et al.  Granulovacuolar degeneration (GVD) bodies of Alzheimer's disease (AD) resemble late‐stage autophagic organelles , 2011, Neuropathology and applied neurobiology.

[26]  P. Hof,et al.  Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. , 2009, ACS chemical biology.

[27]  T. Vu,et al.  Quantitative analysis of multivesicular bodies (MVBs) in the hypoglossal nerve: Evidence that neurotrophic factors do not use MVBs for retrograde axonal transport , 2009, The Journal of comparative neurology.

[28]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[29]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[30]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[31]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[32]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.